.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
Fish and Richardson
Mallinckrodt
Boehringer Ingelheim
Farmers Insurance
Daiichi Sankyo
US Army
Cantor Fitzgerald
QuintilesIMS

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,699,871

« Back to Dashboard

Which drugs does patent 6,699,871 protect, and when does it expire?


Patent 6,699,871 protects JANUMET XR, JANUMET, JANUVIA, and JUVISYNC, and is included in four NDAs. There have been zero Paragraph IV challenges on Juvisync, Janumet XR, , and .

This patent has sixty-four patent family members in forty-two countries.

Summary for Patent: 6,699,871

Title: Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Abstract:The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
Inventor(s): Edmondson; Scott D. (New York, NJ), Fisher; Michael H. (Ringoes, NJ), Kim; Dooseop (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Parmee; Emma R. (Scotch Plains, NJ), Weber; Ann E. (Scotch Plains, NJ), Xu; Jinyou (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:10/189,603
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-002Feb 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-003Feb 2, 2012RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp DohmeJANUMET XRmetformin hydrochloride; sitagliptin phosphateTABLET, EXTENDED RELEASE;ORAL202270-001Feb 2, 2012RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
Merck Sharp DohmeJANUMETmetformin hydrochloride; sitagliptin phosphateTABLET;ORAL022044-002Mar 30, 2007RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Merck Sharp DohmeJANUMETmetformin hydrochloride; sitagliptin phosphateTABLET;ORAL022044-001Mar 30, 2007RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Merck Sharp DohmeJANUVIAsitagliptin phosphateTABLET;ORAL021995-001Oct 16, 2006RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
Merck Sharp DohmeJANUVIAsitagliptin phosphateTABLET;ORAL021995-002Oct 16, 2006RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
Merck Sharp DohmeJANUVIAsitagliptin phosphateTABLET;ORAL021995-003Oct 16, 2006RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
Merck Sharp DohmeJUVISYNCsimvastatin; sitagliptin phosphateTABLET;ORAL202343-004Sep 18, 2012DISCNYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
Merck Sharp DohmeJUVISYNCsimvastatin; sitagliptin phosphateTABLET;ORAL202343-001Oct 7, 2011DISCNYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,699,871

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,125,873Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes► Subscribe
8,440,668Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of type 2 diabetes► Subscribe
8,168,637Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,699,871

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany60236767► Subscribe
Germany122007000056► Subscribe
Germany122008000046► Subscribe
Argentina036114► Subscribe
Austria321048► Subscribe
Austria471148► Subscribe
Australia2002320303► Subscribe
Bulgaria108493► Subscribe
Brazil0210866► Subscribe
BrazilPI0210866► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Medtronic
Federal Trade Commission
Baxter
McKinsey
Queensland Health
Cerilliant
Chinese Patent Office
Colorcon
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot